I'd like to open an account http://www.janelledesrosiers.com/cash-advance-american-loans/ payday loan instant approval  Generic statins will remain the cheap, popular treatment for managing cholesterol. But these companies are investing hundreds of millions of dollars in big Phase III programs with the expectation that they can offer something new and important for people who either can't tolerate statins or don't respond well to them. These are also injected therapies, meaning that they won't come cheap. A high price will potentially net these developers around $3 billion a year for an approved therapy, say some analysts using a common ballpark estimate of peak annual sales. But payers and regulators will also want to see some proof that the drugs will lower the rate of cardiovascular events--the kind of data that won't be quick or easy to gather.